First approved for adults in 2022, the therapy is now cleared for adults and pediatric patients weighing 66 lbs or more with symptomatic obstructive hypertrophic cardiomyopathy.
News|Articles|April 1, 2009
2009 Chain of the Year: Pharmaca
Boulder, Colo.-based Pharmaca, the nation's first European-style integrative retail pharmacy focuses on treating the whole person. Their successful model made them the choice as Drug Topics' 2009 Chain of the Year.
Advertisement
Key Points
Advertisement
Related to this article
The once daily tablet is expected to reach US patients in October 2026.
The label expansion adds patients 12 years of age and older to the once daily alopecia areata indication.
This episode offers a detailed look into the FDA’s recent PCAC meeting and what the future of peptide compounding could lead to for pharmacy professionals.
Eli Lilly’s new indication helps improve medication delivery for adults with type 2 diabetes, reducing annual injections by over 300.
The update adds efficacy and safety data on adults newly diagnosed with pulmonary arterial hypertension.
Orforglipron lowered A1C and body weight more than oral semaglutide 25 mg at 52 weeks, but the estimate comes from an indirect comparison.
Brian Smith, PharmD, explains how direct-to-consumer GLP-1 pathways broaden initial access but endanger long-term patient adherence.
Advertisement
Advertisement
Trending on Drug Topics
1
Technicians Aren't Asking for a Party
2
Indirect Comparison Links Tirzepatide to Greater Weight Loss Than Semaglutide
3
Burnout and PBMs Remain Barriers for Community Pharmacists
4
Infections Fall With Azithromycin for Unscheduled Cesarean Deliveries
5